Anika Therapeutics Inc (ANIK) Forecasted to Post Q3 2019 Earnings of $0.34 Per Share

Anika Therapeutics Inc (NASDAQ:ANIK) – Equities researchers at First Analysis issued their Q3 2019 earnings per share estimates for Anika Therapeutics in a research report issued on Friday, October 26th. First Analysis analyst forecasts that the biotechnology company will earn $0.34 per share for the quarter. First Analysis also issued estimates for Anika Therapeutics’ FY2019 earnings at $1.65 EPS.

Several other research firms have also recently weighed in on ANIK. Zacks Investment Research upgraded Anika Therapeutics from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Monday, August 6th. ValuEngine upgraded Anika Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 3rd. BidaskClub cut Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 29th. Finally, Barrington Research upgraded Anika Therapeutics from a “market perform” rating to an “outperform” rating and set a $48.00 price target for the company in a research note on Friday, July 27th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Anika Therapeutics has an average rating of “Buy” and a consensus target price of $42.00.



ANIK stock opened at $35.55 on Monday. Anika Therapeutics has a 1-year low of $28.54 and a 1-year high of $69.81. The firm has a market capitalization of $518.46 million, a PE ratio of 18.14, a price-to-earnings-growth ratio of 2.29 and a beta of 2.04.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, October 24th. The biotechnology company reported $0.53 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.22. Anika Therapeutics had a return on equity of 9.78% and a net margin of 17.66%. The firm had revenue of $26.79 million during the quarter, compared to analysts’ expectations of $27.12 million. During the same quarter in the previous year, the business earned $0.46 earnings per share. The company’s revenue was down 1.4% on a year-over-year basis.

A number of institutional investors have recently bought and sold shares of the stock. FDx Advisors Inc. increased its position in Anika Therapeutics by 18.0% during the second quarter. FDx Advisors Inc. now owns 8,205 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 1,253 shares during the last quarter. Isthmus Partners LLC increased its position in Anika Therapeutics by 8.4% during the second quarter. Isthmus Partners LLC now owns 18,332 shares of the biotechnology company’s stock valued at $587,000 after acquiring an additional 1,427 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Anika Therapeutics by 81.6% during the second quarter. PNC Financial Services Group Inc. now owns 3,264 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 1,467 shares during the last quarter. Legal & General Group Plc increased its position in Anika Therapeutics by 6.5% during the second quarter. Legal & General Group Plc now owns 29,039 shares of the biotechnology company’s stock valued at $922,000 after acquiring an additional 1,762 shares during the last quarter. Finally, Rhumbline Advisers increased its position in Anika Therapeutics by 5.8% during the second quarter. Rhumbline Advisers now owns 35,848 shares of the biotechnology company’s stock valued at $1,147,000 after acquiring an additional 1,972 shares during the last quarter. Institutional investors own 94.49% of the company’s stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

See Also: Exchange-Traded Funds (ETFs)

Earnings History and Estimates for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply